


## Tubulin polymerization-IN-39

Cat. No.:	HY-151982
Molecular Formula:	C <sub>21</sub> H <sub>21</sub> N <sub>5</sub> O <sub>5</sub>
Molecular Weight:	423.42
Target:	Microtubule/Tubulin
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Tubulin polymerization-IN-39 is a tubulin polymerization inhibitor (IC <sub>50</sub> : 4.9 μM). Tubulin polymerization-IN-39 occupies the colchicine-binding site. Tubulin polymerization-IN-39 inhibits cancer cell proliferation <sup>[1]</sup> .																
<b>In Vitro</b>	<p>Tubulin polymerization-IN-39 (compound 4k) shows antiproliferative activity toward HeLa, HCT116, A549, and T47D, with the IC<sub>50</sub> values of 0.31, 1.28, 3.99 and 10.32 μM, respectively<sup>[1]</sup>.</p> <p>Tubulin polymerization-IN-39 (0.15-0.6 μM, 24 h) increases percentages of HeLa cells at the G2/M phase<sup>[1]</sup>.</p> <p>Tubulin polymerization-IN-39 (0.15-0.6 μM, 24 h) induces HeLa cells apoptosis by increasing cleaved PARP<sup>[1]</sup>.</p> <p>Tubulin polymerization-IN-39 (0.2-0.8 μM, 24 h) inhibits the migration and the tube formation of HUVEC<sup>[1]</sup>.</p> <p>Tubulin polymerization-IN-39 (10 μM) inhibits tubulin polymerization by 78%<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p><b>Cell Viability Assay<sup>[1]</sup></b></p> <table border="1"> <tr> <td>Cell Line:</td> <td>HeLa cells</td> </tr> <tr> <td>Concentration:</td> <td>0.15, 0.3, 0.6 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Increased cyclin B1 protein level and cleaved PARP. Decreased p-cdc2 (the inactive form of cdc2).</td> </tr> </table> <p><b>Cell Migration Assay<sup>[1]</sup></b></p> <table border="1"> <tr> <td>Cell Line:</td> <td>HUVEC</td> </tr> <tr> <td>Concentration:</td> <td>0.2, 0.4, 0.8 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Dose-dependently inhibited HUVEC migration. Prevented HUVEC motility and migration (wound healing assay).</td> </tr> </table>	Cell Line:	HeLa cells	Concentration:	0.15, 0.3, 0.6 μM	Incubation Time:	24 h	Result:	Increased cyclin B1 protein level and cleaved PARP. Decreased p-cdc2 (the inactive form of cdc2).	Cell Line:	HUVEC	Concentration:	0.2, 0.4, 0.8 μM	Incubation Time:	24 h	Result:	Dose-dependently inhibited HUVEC migration. Prevented HUVEC motility and migration (wound healing assay).
Cell Line:	HeLa cells																
Concentration:	0.15, 0.3, 0.6 μM																
Incubation Time:	24 h																
Result:	Increased cyclin B1 protein level and cleaved PARP. Decreased p-cdc2 (the inactive form of cdc2).																
Cell Line:	HUVEC																
Concentration:	0.2, 0.4, 0.8 μM																
Incubation Time:	24 h																
Result:	Dose-dependently inhibited HUVEC migration. Prevented HUVEC motility and migration (wound healing assay).																

### REFERENCES

---

[1]. Chen L, et al. Rational design, synthesis and biological evaluation of novel 2-(substituted amino)-[1,2,4]triazolo[1,5-a]pyrimidines as novel tubulin polymerization inhibitors. Eur J Med Chem. 2022 Dec 15;244:114864.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA